山东博安生物技术股份有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Boan Biotech Announces 2024 Half Year Results: Revenue Grows by 39%, Net Profit Increases by RMB 180 Million 2024-08-27 22:55
Subject Enrollment Completed for International Multicenter Comparative Clinical (Phase 3) Study of Boan Biotech's Denosumab 2024-01-12 21:15
Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA 2023-12-27 20:50
First Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection 2023-10-30 14:51
Boan Biotech's BA1202 Approved for Clinical Trial 2023-05-16 22:02
Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech's Dulaglutide Injection BA5101 in China 2023-05-15 21:58
First Subject Enrolled in Boan Biotech's International Multi-Center Phase 3 Clinical Study for Its Denosumab BA6101 & BA1102 2023-05-04 14:40
1